Navigation Links
Medivation Announces Presentation of Full Top-Line Data From,Dimebon Six-Month Trial at Major International Alzheimer's Disease,Conference

ut Medivation

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the anticipated timing of clinical and regulatory milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006, include more information about factors that could affect the Company's financial and operating results.

CONTACT: Patrick Machado, Chief Financial Officer, Medivation, Inc.,+1-415-543-3470, ext. 201; or Jani Bergan of WeissComm Partners,+1-415-946-1064, for Medivation; or Lori Williams of Baylor College ofMedicine, Office of Public Affairs
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces First U.S. Presentation of Data From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
(Date:11/6/2009)... YORK, Nov. 6 Keryx Biop...conference call on Tuesday, November 10, 2009 at 8...ancial results and business outlook for the remain... of the Company, will host the call. Keryx will a... press release to be issued prior to the call. ,...
(Date:11/6/2009)...ROIT, Nov. 6 Caraco Phar...as launched ketorolac tromethamine ophthalmic solu...Food and Drug Administration (FDA) for Sun Pharma,...ric Acular® opthalmic solution on the first d...etorolac is therapeutically equivalent to Acular&#...
(Date:11/5/2009)...NT RICHMOND, Calif., Nov. 5 /PRNewswire-FirstCall/... ), a specialty pharmaceutical company focused on ...ry products that address important therapeutic nee...t will host a webcast and teleconference with mana...ults on Thursday, November 12, 2009, at 5:00 p.m. ...
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST 2Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 2UPS Chief Named to U S Fund for UNICEFs Board of Directors 57267 1UPS Chief Named to U S Fund for UNICEFs Board of Directors 57267 2National Poll Finds Most Americans Believe Immigration Adversely Affects the Quality and Cost of Healthcare 57264 1National Poll Finds Most Americans Believe Immigration Adversely Affects the Quality and Cost of Healthcare 57264 2San Francisco Home Care Workers Demand that Former Union Officials Come Clean 57261 1San Francisco Home Care Workers Demand that Former Union Officials Come Clean 57261 2San Francisco Home Care Workers Demand that Former Union Officials Come Clean 57261 3
..., June 1 Physicians at the Karmanos Cancer,Instit..., Risk of Second,Lung Cancer in Patients with Prev...llance, Epidemiology, and End Result (SEER) Regist...nual Meeting in Chicago, IL., ( http://www.newsco...ELO ,GO), Karmanos, Praveen Sivakumaran, M.D., al...
... 2 Data To Be Presented Along With Updated Phase 1...O Annual Meeting -, SOUTH SAN FRANCISCO, Calif. a...rd Pharmaceuticals, Inc. (Nasdaq: PARD ), a bioph...nounced positive preliminary results,from its ongo...with,metastatic colorectal cancer (CRC) and update...
Other Medicine Technology:Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women 2Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 2Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 3Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 4Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 5
(Date:11/6/2009)...n, VA)--Three leading scientific organizations spe... a letter to President Obama today expressing thei...e concerning the use of personal protective equipm...ted or confirmed cases of 2009 H1N1 influenza. T...(SHEA), the Infectious Diseases Society of America...
(Date:11/6/2009)...increase, so does the need to exert more pressure ..., Nov. 6 (HealthDay News) -- Hormonal fluctuations..., a new study finds. , Many professional singers ...n,t been known whether this was because of hormone... as the baby grows. , In this study, researchers f...
(Date:11/6/2009)...imitations seem to wane as years go by, researcher...-- New research suggests that people with multiple...developing the disease are more likely to suffer f...rs with the condition. , The findings, published N...sease who relapse within five years of developing ...
(Date:11/6/2009)...million doses now available, with 8 million more d...y News) -- Although the total doses of H1N1 swine ...s 38 million -- 11 million more than a week ago --... able to get one, U.S. health officials acknowledg...percent of children who tried to get vaccinated co...
(Date:11/6/2009)... WAVonline - the Value-Added Distrib...Rider® Product Lines , ...-added distributor of wireless, security, RFID, Vo...ed that it has partnered with Vecima Networks Inc....ting broadband access to cable, wireless and telep...
Breaking Medicine News(10 mins):Health News:Prevention experts urge modification to 2009 H1N1 guidance for health care workers 2Health News:Early Relapse of MS May Mean Fewer Issues Later 2Health News:Most Who Want Swine Flu Shot Can't Get It 2Health News:Most Who Want Swine Flu Shot Can't Get It 3Health News:WAV Distribution Partners with Vecima Networks Inc. 2Health News:WAV Distribution Partners with Vecima Networks Inc. 3
...21 Before your kids are out the schoolroom door a...take a few preventive steps to help protect their ... sure children eat nutritious meals, exercise, sta...ch shows that typical summer activities can trigge...
... for plastic surgery to boost confidence, whereas ...y - 50% of men would change nothing about their ap...liposuction are on the rise , , MANCHESTER, Engla...rviewed by GFK NOP on behalf of Transform Cosmetic...
...First Company to Surpass $100 Million Contribution...ther Disabilities , , CHICAGO, May 21 Safeway (...after raising a record $10.2 million for the organ...ontributions. The national nonprofit recently desi...
... The Oro Organization, LLC, an online lead... with Medical Hair Restoration. , ...The Oro Organization, LLC, an online lead generati...wanted to partner with one of the industry leaders...
... New York Manhattan based personal injury ...rights of bicyclists hit by motor vehicles. , ... -- As subway fares and the cost of gas rise , mor...id Perecman, a leading New York personal injury l...
... Hispanic style cheese known as Queso Fresco or ...fighting obesity and other related health problems...ng dairy foods while consuming a low-calorie diet ...ommended daily intakes of calcium in dairy product...
Other Medicine News:Health News:Protect Your Kids' Hearts: Summer Activity Can Trigger Genetic Disorder, Say Results for Life, Sudden Cardiac Arrest Association 2Health News:Protect Your Kids' Hearts: Summer Activity Can Trigger Genetic Disorder, Say Results for Life, Sudden Cardiac Arrest Association 3Health News:Transform, the Largest Plastic Surgery Clinic, States That Men Are More Vain Than Women 2Health News:Transform, the Largest Plastic Surgery Clinic, States That Men Are More Vain Than Women 3Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 2Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 3Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 4Health News:The Oro Organization, LLC Partners with Medical Hair Restoration to Launch New Website USHairReplacement.com 2Health News:New York Personal Injury Lawyer Seeks to Protect Bicyclists From Harm 2Health News:Hispanic Cheese May Prevent Obesity 2
...full interchangeability between femoral and tibial...molded tibial component with a durable cobalt chro....,The AGC® Knee is indicated for use in total...ized options are required. Unique Cam-and-Groove P...
...holmium laser combines excellent cutting, ablation... bloodless procedures. It is also extremely effect... of all compositions, making it an ideal multipurp...smitted through flexible fibers, it is especially ...
Turnstile Casting Stand™
CEMEX Fast Set
Medicine Products: